Craig Gedye1,2,3,4, Mythily Sachchithananthan1, Robyn Leonard1, Rosalind L Jeffree1,5, Michael E Buckland1,6,7, David S Ziegler1,8,9,10, Manuel B Graeber1,11, Bryan W Day1,12, Kerrie L McDonald1,13,14, Arian Lasocki1,15,16, Anna K Nowak1,17,18. 1. Brain Cancer Biobanking Australia, National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, NSW, Australia. 2. Clinical Research Director, NSW Health Statewide Biobank, Camperdown NSW. 3. School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia. 4. Calvary Mater Newcastle, Waratah, NSW, Australia. 5. Royal Brisbane and Women's Hospital, University of Queensland, Australia. 6. Department of Neuropathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. 7. Discipline of Pathology, Brain & Mind Centre, University of Sydney, NSW, Australia. 8. Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia. 9. School of Women's and Children's Health, University of New South Wales, Sydney, Australia. 10. Children's Cancer Institute, University of New South Wales, Sydney, Australia. 11. Brain Tumor Research Laboratories, Brain and Mind Centre, The University of Sydney, NSW, Australia. 12. QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. 13. Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. 14. Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. 15. Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria. 16. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. 17. School of Medicine and Pharmacology, University of Western Australia, Crawley. 18. Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia.
Abstract
BACKGROUND: A key component of cancer research is the availability of clinical samples with appropriately annotated clinical data. Biobanks facilitate research by collecting/storing various types of clinical samples for research. Brain Cancer Biobanking Australia (BCBA) was established to facilitate the networking of brain cancer biobanking operations Australia-wide. Maximizing biospecimen utility in a networked biobanking environment requires the standardization of procedures and data across different sites. The aim of this research was to scope and develop a recommended clinical annotation dataset both for pediatric and adult brain cancer biobanks. METHODS: A multidisciplinary working group consisting of members from the BCBA Consortium was established to develop clinical dataset recommendations for brain cancer biobanks. A literature search was undertaken to identify any published clinical dataset recommendations for brain cancer biobanks. An audit of data items collected and stored by BCBA member biobanks was also conducted to survey current clinical data collection practices across the BCBA network. RESULTS: BCBA has developed a clinical annotation dataset recommendation for pediatric and adult brain cancer biobanks. The clinical dataset recommendation has 5 clinical data categories: demographic, clinical and radiological diagnosis and surgery, neuropathological diagnosis, patient treatment, and patient follow-up. The data fields have been categorized into 1 of 3 tiers; essential, preferred, and comprehensive. This enables biobanks and researchers to prioritize appropriately where resources are limited. CONCLUSION: This dataset can be used to guide the integration of data from multiple existing biobanks for research studies and for planning prospective brain cancer biobanking activities.
BACKGROUND: A key component of cancer research is the availability of clinical samples with appropriately annotated clinical data. Biobanks facilitate research by collecting/storing various types of clinical samples for research. Brain Cancer Biobanking Australia (BCBA) was established to facilitate the networking of brain cancer biobanking operations Australia-wide. Maximizing biospecimen utility in a networked biobanking environment requires the standardization of procedures and data across different sites. The aim of this research was to scope and develop a recommended clinical annotation dataset both for pediatric and adult brain cancer biobanks. METHODS: A multidisciplinary working group consisting of members from the BCBA Consortium was established to develop clinical dataset recommendations for brain cancer biobanks. A literature search was undertaken to identify any published clinical dataset recommendations for brain cancer biobanks. An audit of data items collected and stored by BCBA member biobanks was also conducted to survey current clinical data collection practices across the BCBA network. RESULTS: BCBA has developed a clinical annotation dataset recommendation for pediatric and adult brain cancer biobanks. The clinical dataset recommendation has 5 clinical data categories: demographic, clinical and radiological diagnosis and surgery, neuropathological diagnosis, patient treatment, and patient follow-up. The data fields have been categorized into 1 of 3 tiers; essential, preferred, and comprehensive. This enables biobanks and researchers to prioritize appropriately where resources are limited. CONCLUSION: This dataset can be used to guide the integration of data from multiple existing biobanks for research studies and for planning prospective brain cancer biobanking activities.
Authors: Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert Journal: Neuro Oncol Date: 2015-08-05 Impact factor: 12.300
Authors: Helen M Moore; Andrea B Kelly; Scott D Jewell; Lisa M McShane; Douglas P Clark; Renata Greenspan; Daniel F Hayes; Pierre Hainaut; Paula Kim; Elizabeth Mansfield; Olga Potapova; Peter Riegman; Yaffa Rubinstein; Edward Seijo; Stella Somiari; Peter Watson; Heinz-Ulrich Weier; Claire Zhu; Jim Vaught Journal: J Proteome Res Date: 2011-06-21 Impact factor: 4.466
Authors: Amélie Gaignaux; Garry Ashton; Domenico Coppola; Yvonne De Souza; Annemieke De Wilde; James Eliason; William Grizzle; Fiorella Guadagni; Elaine Gunter; Iren Koppandi; Katheryn Shea; Tim Shi; Julie A Stein; Mark E Sobel; Gunnel Tybring; Gert Van den Eynden; Fay Betsou Journal: Biopreserv Biobank Date: 2016-05-19 Impact factor: 2.300
Authors: Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak Journal: Cell Date: 2016-01-28 Impact factor: 41.582